NCT06868836 2025-06-27
A Study of JS207 (PD-1/VEGF Bispecific Antibody) in Combination With Chemotherapy in Advanced Non-small Cell Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 2 Recruiting
Clinical Trials
9 trialsNCT02633189 2023-03-24
BEVERLY
National Cancer Institute, Naples
Phase 3 Unknown
NCT05394233 2022-05-27
Tislelizumab +Bevacizumab+pc for Untreated EGFR+ and High PD-L1 Non-squamous NSCLC
Sichuan Cancer Hospital and Research Institute
Phase 2 Unknown
NCT04063449 2019-08-21
Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC
Third Military Medical University
Phase NA Unknown
NCT03992885 2019-06-20
Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.
Tianjin Medical University Cancer Institute and Hospital
Phase 3 Unknown
NCT03671538 2018-09-17
Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin
The First Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT03602027 2018-07-26
Phase I Study of the Combination of Anlotinib With Gefitinib
Second Affiliated Hospital of Nanchang University
Phase NA Unknown
NCT03127319 2018-01-17
A Study of Apatinib Plus Docetaxel for Treatment of Advanced Non-squamous Non-small Cell Lung Cancer With Bone Metastases
Affiliated Hospital of Hebei University
Phase 2 Unknown
NCT01057212 2015-09-07
Trial of Bevacizumab and Ixabepilone for Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
Providence Health & Services
Phase 2 Terminated